Evidence map›Paper›PMID 39443610›Full record

ArticleCommunications biology2024

Cellular fate of a plant virus immunotherapy candidate.

Anthony O Omole, Jessica Fernanda Affonso de Oliveira, Lucas Sutorus, Sweta Karan, Zhongchao Zhao, Barry W Neun, Edward Cedrone, Jeffrey D Clogston, Jie Xu, Michael Sierk and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Design andMaterials today. Bio · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anthony O OmoleAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-2323-2790
Jessica Fernanda Affonso de OliveiraAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA.
Lucas SutorusAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-7380-1843
Sweta KaranAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA.
Zhongchao ZhaoAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA.
Barry W NeunNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.
Edward CedroneNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.
Jeffrey D ClogstonNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.ORCID 0009-0003-6150-3904
Jie XuNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.
Michael SierkCenter for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-0657-0288
Qingrong ChenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Daoud MeerzamanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Marina A DobrovolskaiaNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.ORCID 0000-0002-4233-9227
Nicole F SteinmetzAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA. nsteinmetz@ucsd.edu.ORCID 0000-0002-0130-0481

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
Toward translation of a plant virus-based in situ vaccination nanotechnologyR01CA274640 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, RANJAN, ASHISH · 2022 to 2025
$2.5M
Alfred P. Sloan Foundation G-2020-14067American Cancer Society (American Cancer Society, Inc.) MBGI-23-1030244-01-MBGNCI NIH HHS 75N91019D00024NCI NIH HHS R01 CA224605NCI NIH HHS R01 CA253615NCI NIH HHS R01 CA274640U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 75N91010D00024
6 · The paper itself

Abstract

Cowpea mosaic virus (CPMV) is a plant virus that is currently being developed for intratumoral immunotherapy. CPMV relieves the immune system from tumor-induced immunosuppression; reprograms the tumor microenvironment to an activated state whereby the treated and distant tumors are recognized and eradicated. Toward translational studies, we investigated the safety of CPMV, specifically addressing whether pathogenicity would be induced in mammalian cells. We show that murine macrophage immune cells recognize CPMV; however, there is no indication of de novo viral protein synthesis or RNA replication. Furthermore, we show that CPMV does not induce hemolysis, platelet aggregation and plasma coagulation amongst other assays in human blood and immune cells. Taken together, we anticipate that these results will reinforce the development of CPMV as an immunotherapeutic platform.

Indexed as

ComovirusImmunotherapyAnimalsHumansMacrophagesMice

Identifiers

PMID39443610
PMCPMC11499861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.